Business Context and Reporting Period
This Form 8-K Current Report from Corbus Pharmaceuticals Holdings, Inc. (CRBP) covers events occurring on May 15, 2025. The filing details the results of the Company's Annual Meeting of Stockholders and a subsequent Board of Directors appointment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Corporate Actions
Annual Meeting Voting Results
- Election of Directors: All seven nominees were elected to one-year terms. Voting results included significant broker non-votes (2,281,655) across all candidates.
- Yuval Cohen: 6,681,546 For / 65,244 Withheld
- Alan Holmer: 6,678,977 For / 67,813 Withheld
- Rachelle Jacques: 6,634,539 For / 112,251 Withheld
- John Jenkins: 6,681,768 For / 65,022 Withheld
- Anne Altmeyer: 6,677,977 For / 68,813 Withheld
- Yong Ben: 6,667,049 For / 79,741 Withheld
- Winston Kung: 6,568,610 For / 178,180 Withheld
- Ratification of Auditors: The appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was approved (8,841,947 For / 154,305 Against).
- Executive Compensation: The advisory vote on executive compensation was approved (6,519,904 For / 215,784 Against).
Board Leadership Change
Effective May 15, 2025, the Board appointed Rachelle Jacques as Chair of the Board. She succeeds Alan Holmer, who will remain a member of the Board.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the shareholder vote and the Board appointment.
Investor Verification Checklist
- Verify the total number of shares outstanding and the percentage of votes represented by the "Broker Non-Votes" (2,281,655) to assess shareholder engagement levels.
- Confirm the strategic rationale for appointing Rachelle Jacques as Chair and the continued role of Alan Holmer on the Board.
- Review the definitive proxy statement referenced in the filing for detailed executive compensation metrics and director biographies.
- Check subsequent filings (e.g., 10-Q or 10-K) for the financial data absent from this 8-K.